Ascendis Pharma A/S (ASND) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Ascendis Pharma (ASND) Q4 2025: Yorvipath Drives 39% Revenue Growth as Global Launch Scales
  June 15, 2026
• Ascendis Pharma (ASND) Q4 2025: Yorvipath Uptake Lifts 187M Euro, Sets Stage for 10-Country Expansion
  June 15, 2026
• Ascendis Pharma (ASND) Q1 2026: Operating Margin Hits 22% as Diversified Endocrine Portfolio Scales
  May 08, 2026
• Ascendis Pharma (ASND) Q3 2025: Yorvipath Patient Base Expands to 4,250 as Global Launch Drives Operating Profit
  November 13, 2025
• Ascendis Pharma (ASND) Q2 2025: YorbaPath Revenue Doubles, Accelerating Blockbuster Trajectory
  August 08, 2025
• Ascendis Pharma (ASND) Q1 2025: Yorvipath Drives 230% Revenue Surge, Anchoring Rare Disease Leadership
  July 04, 2025
• Ascendis Pharma (ASND) Q3 2024: Skytrofa Volume Up 60% as YorvaPath U.S. Launch Nears
  November 14, 2024
• Ascendis Pharma (ASND) Q2 2024: Skytrofa Net Revenue Down 27% as Market Access Reset Reshapes Growth Path
  September 03, 2024
• Ascendis Pharma (ASND) Q1 2024: Skytrofa Revenue Doubles, Lifts Path to Cash Flow Breakeven
  May 02, 2024
• Ascendis Pharma (ASND) Q4 2023: Skytrofa Revenue Jumps 37% QoQ as Streamlining Unlocks Breakeven Path
  February 07, 2024

Browse all companies